Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Get Free Report) dropped 5.9% during mid-day trading on Thursday. The company traded as low as $0.7101 and last traded at $0.7101. 53,588 shares traded hands during trading, a decline of 17% from the average session volume of 64,763 shares. The stock had previously closed at $0.7550.
Analyst Ratings Changes
Separately, Weiss Ratings downgraded Genenta Science from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, September 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Genenta Science currently has an average rating of “Sell”.
Read Our Latest Stock Analysis on GNTA
Genenta Science Stock Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in Genenta Science stock. SmartHarvest Portfolios LLC raised its stake in Genenta Science S.p.A. Unsponsored ADR (NASDAQ:GNTA – Free Report) by 656.1% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 134,447 shares of the company’s stock after purchasing an additional 116,666 shares during the period. SmartHarvest Portfolios LLC owned 0.57% of Genenta Science worth $90,000 as of its most recent SEC filing. Institutional investors and hedge funds own 15.13% of the company’s stock.
Genenta Science Company Profile
Genenta Science S.p.A. (NASDAQ: GNTA) is a clinical-stage biotechnology company developing cell and gene therapies for cancer. The company’s approach uses a patient’s own hematopoietic stem cells, genetically modified outside the body to produce therapeutic proteins and deliver them to the tumor microenvironment.
Genenta’s lead investigational product, Temferon, is designed to generate interferon-alpha within solid tumors. The therapy is being studied primarily in glioblastoma, an aggressive form of brain cancer, with the goal of concentrating treatment in the tumor while limiting exposure to healthy tissues.
Further Reading
- Five stocks we like better than Genenta Science
- Want Private-Market Access to Kalshi and Polymarket? Try This ETF
- Levi’s Stock Dip Reveals Value Opportunity Despite Q3 Headwinds
- PepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value
- Alphabet’s $1.8 Billion Black Hills Deal Powers AI Data Center Push
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
